Active — Not RecruitingEarly Phase 1

Local Injection Methylene Blue Combined With Radiation in HNSCC Patients

Taiwan10 participantsStarted 2025-08-01

Plain-language summary

The goal of this clinical trial is to investigate the effectiveness of Methylene Blue (MB) as a radiosensitizer in treating head and neck squamous cell carcinoma (HNSCC) that has recurred locally and is resistant to radiation therapy. It will also assess the safety of Methylene Blue. The main questions it aims to answer are: Does Methylene Blue improve the outcomes for patients with recurrent HNSCC receiving radiation therapy? What side effects do participants experience while receiving Methylene Blue? Participants will: Receive weekly injections of Methylene Blue or placebo into the tumor over six weeks. Undergo six weeks of concurrent radiation therapy. Be monitored regularly for treatment effects and document any side effects experienced during the trial. This single-center clinical trial intends to recruit 10 eligible patients diagnosed with locoregional recurrence of HNSCC that is resistant to previous radiotherapy.

Who can participate

Age range20 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. . Histologically confirmed squamous cell carcinoma of head and neck.
✓. . Locoregional recurrence.
✓. . After standard treatment of R/M HNSCC.
✓. . Measurable disease. Defined as presence of at least one lesion as being ≥10 mm in at least one dimension measured with conventional computed tomography (CT) or ≥10 mm in at least one dimension measured with spiral CT scan or magnetic resonance imaging (MRI).
✓. . Lesion selection criteria - at least 1 lesion to be injected must be measurable and greater than or equal to 1.5 cm and longest diameter not exceed 10 cm in principle.
✓. . ECOG performance status ≤2.
✓. . Age ≧20 years old; and life expectancy of at least 12 weeks.
✓. . Prior treatments with radiation therapy for palliative management of non-target lesion metastatic disease is permitted provided that at least 2 weeks have elapsed since the last fraction of radiation therapy, disease progression has been documented and all treatment related adverse events are ≦ grade 1 at the time of registration.

Exclusion criteria

What they're measuring

Any unexpected severe adverse event resulting from the combination treatment.

Timeframe: "through study completion, an average of 1 year"

Trial details

NCT IDNCT07435415

SponsorChina Medical University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12-31

View on ClinicalTrials.gov More Head and Neck Cancer trials